Losmapimod Overcomes Gefitinib Resistance in Non-small Cell Lung Cancer by Preventing Tetraploidization

Losmapimod Overcomes Gefitinib Resistance in Non-small Cell Lung Cancer by Preventing Tetraploidization

The epidermal growth factor receptor (EGFR) is known to play a critical role in non-small cell lung cancer (NSCLC). Constitutively active EGFR mutations, including in-frame deletion in exon 19 and L858R point mutation in exon 21, contribute about 90% of all EGFR-activating mutations in NSCLC. Althou...

Full description

Bibliographic Details
Main Authors: Yiu To Yeung, Shuying Yin, Bingbing Lu, Suyu Fan, Ran Yang, Ruihua Bai, Chengjuan Zhang, Ann M. Bode, Kangdong Liu, Zigang Dong
Format: Article
Language:English
Published: Elsevier 2018-02-01
Series:EBioMedicine
Subjects:
Non-small cell lung cancer (NSCLC)
Gefitinib resistance
Tetraploidization
p38 mitogen activating protein kinase (MAPK)
Losmapimod
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396418300215

Internet

http://www.sciencedirect.com/science/article/pii/S2352396418300215

Similar Items